News chronological

Showing 10 items before 1119153

NYTIMES (Maya Salam) - ‘National Treasure,’ the Over-Engineered, Delightfully Dumb U.S. History Lesson

Nicolas Cage, Diane Kruger and Justin Bartha raced from conspiracy theory to conspiracy theory in this 2004 blockbuster about stealing the Declaration of Independence.

NYTIMES (Sheri Fink) - Why Epidemics Breed Rage at Health Workers

Some people have fought Ebola containment measures in the Democratic Republic of Congo. Scholars have seen similar responses across societies and throughout history.

NYTIMES (Reis Thebault and Kellen Browning) - Can Arizona Republicans Stop Feuding Long Enough to Win Back the State?

Some Republicans fear the party is poised to repeat past mistakes by nominating candidates in Tuesday’s primaries who are viewed as too extreme to sway moderate voters.

NYTIMES (Cade Metz) - Why Silicon Valley Can’t Stop Looking Over Its Shoulder at China

Chinese companies are offering artificial intelligence that is nearly as good as the leading U.S. technologies, but it’s still America’s race to lose.

AXIOS (Maria Curi) - The secret Trump administration battle to fight Chinese AI

The Trump administration is showing signs it could ban cutting-edge Chinese AI models — a momentous move that could lock in dominance by OpenAI and Anthropic. Why it matters: Parts of the administration have tried to implement de facto bans on foreign open-source models before, knowledgeable sources tell Axios. Last week's rise of Chinese model Kimi is reigniting those efforts. Pro-competition voices fear the implications. - U.S. companies are increasingly using open-source models from China because they're cheaper and, as seen by the advent of Kimi , just about as good as the domestic technology. Behind the scenes: The Commerce Department last year considered adding multiple Chinese AI labs to its "Entity List," which would…

How does outside White House AI adviser David Sacks characterize the current state of AI policy and the motivations of leading closed labs?
David Sacks stated that the U.S. is at a "critical inflection point in AI policy" and suggested that leading closed labs, which currently form a duopoly in AI model revenue, want the government to eliminate their open-source competition.
Q&A ID eb88b549-27af-434e-9586-e5a257974688
What alternative methods besides an outright ban could the administration use to encourage U.S. companies to drop Chinese AI platforms?
The administration could use procurement rules, Entity List threats, public pressure campaigns, and efforts to highlight potential backdoors, lack of security, and governance issues associated with Chinese models.
Q&A ID f4714c04-fa47-41fb-b0b3-2365eb696115
Why are U.S. companies increasingly utilizing open-source models from China, such as Kimi?
U.S. companies are using them because they are cheaper and, as seen with the advent of Kimi, are considered to be nearly as good as domestic technology.
Q&A ID e3a80b27-b51e-4a14-a0bc-a2f4f6fb8c10
What type of executive order was considered by the White House to regulate the hosting of Chinese AI models?
The White House considered an executive order requiring U.S. companies to guarantee security and take liability if a breach occurred if they chose to host Chinese models.
Q&A ID 03ca881f-e068-4064-8036-3f1a6ff36b59

AXIOS (Adriel Bettelheim) - How AI is supercharging drug development

Artificial intelligence is dramatically speeding up drug development — and a proprietary survey shows how it's priming a bigger automation push that's changing the trajectory of early stage pharma research. Why it matters: The TD Cowen survey of 80 biopharma leaders and insiders finds AI is compressing drug developers' preclinical costs and timelines by as much as 70%. - That's fueling demand for cutting-edge software, sequencing tools and computer models that will help churn out more experimental treatments in the next five years. The big picture: AI can't replace scientific intuition. But the way it can streamline the grueling R&D before human testing begins is making computer screens as important a feature of drug design as…

What are the primary threats to U.S. research efforts mentioned in the report?
China's biotech buildup threatens U.S. research efforts by offering cheaper labor and quick turnaround times, which are attracting billions in new investment.
Q&A ID 15220119-eb77-46eb-b68c-d77e336ab2dd
What is the current status of AI-discovered drugs regarding FDA approval?
AI has not yet discovered a drug that has won Food and Drug Administration (FDA) approval.
Q&A ID 76b2efc8-c4b2-4862-9656-4c58f8619466
What specific types of software are expected to see the strongest upside in demand by 2028?
Demand is expected to be strongest for advanced software that can simulate biological processes, predict how two drugs interfere with each other, or adjust dosages for pregnant women and newborns.
Q&A ID f7d295a1-69c3-40e3-a388-36a9071f59b4
How might the Trump administration's push to reduce animal testing in biomedical research influence pharmaceutical research methods?
It will likely pivot more work toward computational tools, 3D human tissue models, and other alternatives that predict the toxicity of a compound.
Q&A ID cd8ef136-23bb-4b34-b8ce-fc834cdeec18